M
Minori Koshiji Rosales
Researcher at Merck & Co.
Publications - 11
Citations - 1441
Minori Koshiji Rosales is an academic researcher from Merck & Co.. The author has contributed to research in topics: Trastuzumab & Medicine. The author has an hindex of 4, co-authored 6 publications receiving 831 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Journal ArticleDOI
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Daniel V.T. Catenacci,Yoon-Koo Kang,Haeseong Park,Hope E. Uronis,Keun-Wook Lee,Matthew C.H. Ng,Peter C. Enzinger,Se Hoon Park,Philip J. Gold,Jill Lacy,Howard S. Hochster,Sang Cheul Oh,Yeul Hong Kim,Kristen A. Marrone,Ronan J. Kelly,Rosalyn A. Juergens,Jong Gwang Kim,Johanna C. Bendell,Thierry Alcindor,Sun Jin Sym,Eun-Kee Song,Cheng Ean Chee,Yee Chao,Sunnie Kim,A. Craig Lockhart,Keith L. Knutson,Jennifer Yen,Aleksandra Franovic,Jeffrey L. Nordstrom,Daner Li,Jon M. Wigginton,Jan K Davidson-Moncada,Minori Koshiji Rosales,Yung-Jue Bang +33 more
TL;DR: These findings serve as proof of concept of synergistic antitumour activity with the combination of an Fc-optimised anti-HER2 agent (margetuximab) along with anti-PD-1 checkpoint blockade (pembrolizumab).
Journal ArticleDOI
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Daniel V.T. Catenacci,Minori Koshiji Rosales,Hyun Cheol Chung,Harry H. Yoon,Lin Shen,Markus Moehler,Yoon-Koo Kang +6 more
TL;DR: The design and rationale of the randomized, open-label, Phase II/III MAHOGANY trial evaluating margetuximab plus retifanlimab with/without chemotherapy and tebotelimab with chemotherapy in first-line unresectable metastatic/locally advanced gastroesophageal junction adenocarcinoma are described.
Journal ArticleDOI
KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).
Luis A. Diaz,Dung T. Le,Takayuki Yoshino,Thierry André,Johanna C. Bendell,Minori Koshiji Rosales,S. Peter Kang,Bao Lam,Dirk Jäger +8 more
TL;DR: A small number of mCRCs with MSI-H have abundant lymphocyte infiltrates and strong expression of immune checkpoints, leading to high levels of MSI, and these CRCs are enrolled in the phase 2 trial ofTPS877.
Journal ArticleDOI
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
Daniel V.T. Catenacci,Y.-K. Kang,Harry H. Yoon,Byoung Yong Shim,S.T. Kim,D. Oh,Alexander I. Spira,Susanna Varkey Ulahannan,Eric J. Avery,Patrick McKay Boland,J. Chao,H.C. Chung,F. Gardner,Samuel J. Klempner,K.‐W. Lee,S‐C. Oh,Julio Peguero,Mohamad Bassam Sonbol,Lin Shen,Markus Moehler,J Y Sun,D. Li,Minori Koshiji Rosales,H. Park +23 more
TL;DR: In this article , the authors proposed a chemotherapy-free regimen of combined margetuximab/retifanlimab as first-line treatment in double biomarker-selected patients demonstrated a favorable toxicity profile compared with historical outcomes using chemotherapy plus trastuzumab.